ProPhase Labs, Inc. Stock Split Ratio
ProPhase Labs, Inc. (PRPH) had Stock Split Ratio of 10.00% as of 2025-12-02, per its 10-K filed 2026-06-01.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-06-01
- 2025-12-02: Stockholders' Equity Note, Stock Split, Conversion Ratio 10.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2025-12-02 | 10.00% 10-K · filed 2026-06-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |